Opendata, web and dolomites

H I C I SIGNED

Transcriptional and epigenetic control of tissue regenerative HB-EGF in autoimmune CNS inflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 H I C I project word cloud

Explore the words cloud of the H I C I project. It provides you a very rough idea of what is the project "H I C I" about.

glial    exacerbated    regulation    induction    modifications    nervous    inflammation    nasal    explore    stages    degenerative    knocking    inhibited    concomitantly    gain    promoter    prevented    ahr    disease    mediated    validate    astrocytes    cells    mechanisms    risk    blockade    activation    methylation    heparin    fail    hydrocarbon    ligands    progressive    neurological    chronic    translational    diseases    accumulation    induce    ms    biomarkers    binding    worsening    epigenetic    recover    destruction    unknown    transcription    serum    animal    regenerative    egf    untreatable    preliminary    inhibit    sclerosis    discovered    dna    central    astrocytic    methyltransferase    autoimmune    fluid    knock    inflammatory    sites    protective    dnmt1    multiple    cns    deficits    aryl    hb    monitoring    status    patients    decreased    model    acute    ligand    revealed    led    therapeutically    regeneration    receptor    therapy    therapeutic    tissue    cerebrospinal   

Project "H I C I" data sheet

The following table provides information about the project.

Coordinator
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙706 €
 EC max contribution 1˙499˙706 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2025-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 1˙499˙706.00

Map

 Project objective

Multiple Sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS), in which chronic inflammation and failure of regenerative mechanisms lead to progressive tissue destruction and accumulation of neurological deficits. Glial cells such as astrocytes induce regenerative processes in acute inflammation, but fail to inhibit tissue destruction for yet unknown reasons in chronic disease. In preliminary studies, we identified heparin-binding EGF-like growth factor (HB-EGF) in astrocytes as novel tissue protective factor. Indeed, knock-down of HB-EGF in astrocytes led to exacerbated disease and failure to recover in an animal model of MS. Promoter studies revealed induction of HB-EGF by the ligand-induced transcription factor aryl hydrocarbon receptor (AHR) in acute inflammation. However, astrocytic HB-EGF decreased in chronic stages concomitantly with progressive disease worsening. Analyses of AHR binding sites in the HB-EGF promoter revealed epigenetic modifications mediated by DNA-Methyltransferase 1 (DNMT1) in chronic inflammation, which inhibited promoter activation by AHR. Knocking down DNMT1 prevented epigenetic changes and increased HB-EGF production in chronic stages. Thus, we have discovered astrocytic HB-EGF as a novel regenerative factor and its regulation by AHR and DNMT1, which could be targeted therapeutically to enhance tissue regeneration in chronic stages. In this project, we will define the role of HB-EGF in acute and chronic autoimmune CNS inflammation (Aim 1), its regulation by AHR and DNMT1 (Aim 2), and the therapeutic value of nasal HB-EGF application or DNMT1 blockade (Aim 3). In a translational approach, we will validate AHR ligands, HB-EGF and HB-EGF promoter methylation status in serum and cerebrospinal fluid of MS patients as novel biomarkers for MS (Aim 4). These high risk/high gain studies explore novel concepts for monitoring and therapy of yet untreatable stages of MS and other degenerative diseases of the CNS.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "H I C I" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "H I C I" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ChaperoneRegulome (2020)

ChaperoneRegulome: Understanding cell-type-specificity of chaperone regulation

Read More  

EffectiveTG (2018)

Effective Methods in Tame Geometry and Applications in Arithmetic and Dynamics

Read More  

PSYDISC (2020)

Developing and Testing the Psychological Distance to Science Model

Read More